Three Amigos of Biotech

BEAM, TWST & FATE

It looks like having a real (positive) P/E, may be about to be important.

The prior biotech update said that so far, no P/E, negative P/E, and ‘no money down’ was not affecting the sector.

That is, until now.

Well, ok. I made up the ‘no money down’, part. 🙂

That little jest does not take away from the fact, biotech SPBIO, and its top three weightings, BEAM, TWST and FATE, have all reversed, decisively to the downside.

For the week just ended, BEAM is down – 22.86%, TWST down – 19.18%, and FATE down – 14.16%.

Back at the ranch in the IBB index, Moderna (MRNA) is also down – 14.65% for the week.

So, we have confirmation the entire industry is now continuing its downward course.

Contrast the reversal of index SPBIO, at – 7.04%, with S&P (SPY) at – 1.16%, and the market itself is telling us where to go for opportunity (not advice, not a recommendation).

At this point, all three amigos (BEAM, TWST, FATE) are in downward trading channels.

Trading channel for BEAM is the most aggressive. The weekly chart is below.

Beam Therapeutics (BEAM) Weekly

If BEAM maintains its channel for the rest of this year, the chart below shows the target area(s) for price action.

The coming week may let us know if this channel will be confirmed or negated.

Recall, the S&P is topping out and appears to be reversing.

Goldman says the squeeze is over but that ‘downside is limited’.

We’ll see.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

The Moderna (MRNA) Channel

Chief Cook & Bottle Washer

We’re about forty minutes into the session; Moderna (MRNA) has just confirmed the up-thrust reversal discussed in the last update.

It took seven trading days for MRNA, to post a new weekly low below 160.06.

That was plenty of time to perform research like finding this bullish outlook and deciding for oneself, whether to be bull or bear.

This update is brief.

Two charts of MRNA, are shown below.

Price action’s in a channel with the right side declining at approx: – 93.7%, annualized.

Moderna MRNA, Weekly Bar

Compressed version.

We’re using MRNA, as the proxy for the biotech sector.

The previous report showed a weak 23.6%, retrace and potential reversal.

With today’s print below 160.06, it looks like an initial confirmation of the right-side trend line (not advice, not a recommendation).

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

The Moderna Reversal

‘Whistling Past The Graveyard’

Moderna (MRNA) appears likely to join the ranks of Carvana (CVNA), with a decline from all-time highs that’s well over -90%.

Even a ‘modest’ projection (as we’ll see below) puts the downside potential for MRNA, far below current levels.

Starting with the weekly chart, MRNA, has just barely retraced upward to an anemic 23.6%, before breaking to the downside.

Moderna MRNA, Weekly Chart

Zoom version below

The Wyckoff up-thrust (reversal), will be confirmed if/when MRNA pushes below last week’s low of 160.06

Projected Decline Over -90%

Unless it’s negated, the weak retrace (23.6%), tells us that MRNA, is probably just getting started to the downside.

Using a modest 1 : 1, projection from current levels, we have MRNA’s downside potential to the 45-area; representing a decline from all-time highs, of approximately -90.9%.

However, for such a weak equity (at this point), the decline also has the possibility to go a bit further, to a 1 : 1.382 projection (shown as the lower arrow).

Declining to the 27-area, would put MRNA, down a stiff -94.6%, from all-time highs.

If MRNA gets to those levels, that’s when the fun starts.

Class Action?

Recall, we’re using the Carvana Crash as the model, right?

Let’s hold that thought and go way back to October 17th, of last year. Reviewing the first bullet item of this post; some of which is repeated below, it said:

“Whenever a high-flyer darling stock changes course and reverses down in a big way, the lawsuits start.

‘Investors’ only know one direction … up.

They figure they’re so smart, any decision from them that does not work out, must be someone else’s fault.

Class Action for Moderna (with discovery) may be dead ahead.

Let’s start our stopwatch and see how long it takes for the first ‘Notice’.”

Getting back to Carvana (CVNA), it posted recent lows on July 14th this year. That was a decline (from all-time highs) of -95%.

Three weeks after that low, and just days ago on August 4th, we get ‘Notice of Class Action‘.

Tick, Tock …

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

‘Pivot’, or ‘The Channel’

Who’s On First?

Evidently, according to this out on ZeroHedge, stocks will be a good buy when the Fed pivots; apparently getting back to 2%, inflation.

So many lies, half-truths and pre-suppositions, all in one sentence. Let us count the ways.

Actually, let’s not.

At this point in time, one does not want to draw any undue attention.

A better idea is to see what the market’s saying about itself. This is the crux of Wycoff analysis.

Wyckoff stated a century ago (1902, to be exact), stock prices moved based on an energy of their own; at times, completely disconnected from fundamentals.

Looking at those markets and from my own tracking spreadsheet, 106, indices or equities are currently monitored.

That list will change over time but it’s typically around 100 or more ticker-symbols.

Of that number, the following are those currently in a downward sloping trading channel.

The List

Looking at the charts on a weekly basis:

AEM, BBY, C, CAT, COF, CORN, CPER, CVX, DIA, DJ-20, DJUSBM, FCX, FMC, GDXJ, GLD, GM, HYG, IYR, PLD, SLV, TSM, USB, USO, WY, XLF, XOM, XOP

Others that may be about to confirm their channel:

IBB, MRNA, SPBIO, SPY

The Charts

Two examples are from the above list; the important part is we’re going to choose ‘heavy industry’.

Since nobody can seem to figure out the definition of ‘recession’, we’ll help them out a bit.

Caterpillar CAT, Weekly Chart:

The right trendline’s declining at approximately -67%, on an annualized basis.

Next up, FMC Corp.

FMC Corp., Weekly Chart:

FMC’s in a little better position with its right side declining at ‘only’ – 55%, annualized.

But wait, there’s more.

Since we’re on a roll; let’s throw in a bonus and include a market directly connected to the economy; Copper.

Bonus Chart:

United States Copper Fund, CPER, Weekly

Even with last week’s continued but fading S&P, short covering, CPER could not close higher.

Ruh-Roh.

CPER is heading south at a whopping -79%, annualized.

Ok, one more.

This one’s not quite yet confirmed but we’ll probably get a decision this coming week.

We saved the best (worst) for last

Moderna MRNA, Weekly

From the lows during the week ended June 17th, to last Friday’s high, was a Fibonacci 8-Weeks.

It’s also a near exact Fibonacci 23.6%, retrace.

On top of that, price action is testing the underside of resistance formed during the break below the 200-level at the beginning of the year.

If next week we see a pivot lower, MRNA’s potentially declining at a well-deserved, -84%, annualized.

Summary

We don’t have to listen to supposed experts and analysis ‘banter’. The charts themselves tell us the next probable direction, i.e., down

Who’s on First and What’s on Second.

The media?

Well, let’s just say they might find this link useful.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Last Time … is not … This Time

The Rule of Alternation

That’s it in a nutshell. What happened last time, won’t happen this time.

The market reveals its own secrets; you just have to know where to look.

An entire industry has been (purposely) built to make sure the ‘average investor’ never finds the truth of the markets.

That industry is the financial analysis industry; the one with the P/E ratios, Debt-to-Equity, and so on.

Sure, it was a tongue-in-cheek post to use the fact that Carvana had no P/E (linked here).

I’m not certain if they ever had a P/E; probably not.

However, that financial, i.e., fundamental(s) fact, did not keep the stock from going up over 4,529%, in four years.

It should be noted, the Carvana analysis was done on a Saturday (as has this one). At the very next trading session, CVNA posted lower, started its decline in earnest and never looked back.

Not saying that exact thing (timing it to the day) will happen with our next candidate real estate; as said before, part of Wyckoff analysis (a lot of it, actually) is straight-up intuition.

The good part from a computer manipulated and controlled market perspective, intuition can’t be quantified.

So, that’s your edge.

Let’s move on to ‘last time is not this time’ and see what the real estate market IYR, is telling us.

Weekly Chart, IYR

We’ve got the weekly un-marked chart of IYR, below.

The ‘alternation’ is there.

Here it is, close-up.

The first leg lower had some initial smoothness but quickly became choppy and overlapping.

Not so, now.

We’re essentially heading straight down.

Fundamentals

From a fundamental standpoint, real estate is finished. However, it’s been finished for a long time.

The fundamentals won’t and can’t tell anyone what’s likely to happen at the next trading session … or any other session.

The market itself (shown above) is saying the probabilities are for a continued decline; posting smooth long bars until some meaningful demand is encountered.

As shown on the last post, if the trading channel is in-effect, that (chart) demand is a long way down.

Positioning

Shorting IYR via DRV, has been covered in previous posts (search for DRV-22-02).

The following weekly chart, is marked up with two arrows.

Arrow No. 1

Initial short position via DRV was opened late in the day on April 28th; the day before the market broke significantly lower (not advice, not a recommendation).

Arrow No. 2

As the market headed lower during the week just ended, the size of the DRV position was increased by 36%.

Currently, the gain on the total position is about +22%.

At this juncture, the DRV stop is located well in the green in the unlikely event we get a sharp IYR, upward move in the coming week.

Summary

Under ‘normal’ conditions one could expect some kind of upward bounce in the days ahead.

However, as shown already with big cap leader PLD, the situation’s anything but normal.

Highlighted in earlier posts, biotech is leading the way with SPBIO, currently down – 59.8%, from its highs.

Biotech IBB, with chief cook and (globalist) bottle washer Moderna (MRNA), is down – 36.2%.

As Dan from i-Allegedly has stated time and again, we’re already in a depression.

So, buckle your seatbelt Dorothy …

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

‘Heart Failure’ … The New Normal

… What It Could Mean For Biotech

So, now it starts.

This just out from ZeroHedge, linked here, shows the ‘elephant’ has begun to go mainstream.

Another chess-move.

At least one previous post (No.1, linked here), has shown the phenomenon is not a one-off event.

Now, according to the link above, there’s an estimated 300,000 affected … and we’re just getting started.

Insiders Sell … Retail Buys

Do those at the highest levels know their customer base is about to evaporate on a world-wide basis?

While they may not know every detail, they at least know something’s up. Steven Van Metre discusses the insider selling in his latest update, linked here.

Front End Phenomenon

We’re still at the beginning stages of an event that in the opinion of this author, is going to last the lifetime of those reading this post.

‘Hyperbolic statement’ one might say.

To that, I would counter with this; when it was posted, the ‘elephant’ was hyperbolic as well.

Now? Not so much.

Keeping that long range thinking in mind also keeps one from choosing the ‘insane’ human behaviors discussed by Dan (I Allegedly) in his latest post.

So, let’s take a look at what type of insanity we have going on in the markets today.

Of course, that points us to our chief cook and bottle washer, biotech (IBB).

Biotech, IBB

When we last left our hero, savior, and protector of all that is natural immunity, the biotech discussion was on Moderna (MRNA).

The thrust higher, detailed in this post was thought to be too fast for a sustained reversal. Well, it was right and wrong at the same time.

Moderna wound up reversing … sort of.

At the same time, the biotech sector headed lower to support and is now moving higher.

The weekly IBB, chart has the support (lower blue line) and potential up-thrust location (also 50%, retrace) identified.

The zoom shows the narrow gap between the weekly bars and 50% retrace.

If price action makes it past the resistance bars and into the gap, IBB would then be in up-thrust position (not advice, not a recommendation).

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279


Panic In The Streets …

Remain Calm. All, Is Well.

All, Is Well !!!

It certainly feels like Animal House, doesn’t it?

A bunch of idiots running around, glued to the mainstream narrative.

However, let’s not digress but rather get to the chief cook and bottle washer at hand.

Moderna (MRNA) and Biotech (IBB).

Biotech: MRNA, IBB

Moderna’s move above resistance (‘Target’ level in this update) seems too fast for up-thrust and reversal.

It could reverse from here.

However, the more likely scenario is the mainstream milks this whole thing all the way to Christmas and beyond.

That brings us to the sector itself, IBB:

We’ll go straight to the marked-up (daily) chart.

It’s starting to look familiar isn’t it?

Spring-to-Up-Thrust … Spring-to-Up-Thrust

But wait … there’s more!

A Fibonacci 21-Days from the most recent IBB, low on November 23rd, puts the date at December 22; The Winter Solstice.

How convenient.

Of course, anything can happen between now and then. At least we have a potential target and scenario.

As with the gold miner’s (GDX) short that’s still on-going (not advice, not a recommendation), we get to see how it all plays out.

Will Biotech, IBB, be in up-thrust (reversal) position, on or around December 22nd?

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

… Cue The ‘Hype’

Right On Schedule … A New ‘Variant’

Seems like just yesterday, we were saying:

“There’s all kinds of nastiness in the guise of ‘new strains’ out there; likely to raise their heads before Christmas and probably after as well.”

Wait, … that really was, yesterday.

So, now we have the ‘Nu variant’.

Get it? A, new variant. 🙂

The ‘Epsilon’ variant (from the idiot in Brave New World) is probably being saved for last … because if anyone’s still believing the hype by that time, it won’t matter … they’ll be fully ‘boosted’.

That doesn’t mean the pros can’t make money off the herd … while there still is a herd.

Which brings us to today’s underside test action of MRNA.

Moderna (MRNA):

Well, that retrace was quick.

First, let’s show yesterday’s weekly chart.

And now, today’s

It’s true that price action is testing the underside.

However, if we go to the daily chart (below), we can see if price action can make it just a bit higher … to the 360 – 380 area, then we have an up-thrust (potential reversal) condition.

The chart looks similar to our gold (GLD) up-thrust target, linked here for reference.

Recall, for that set-up, it took two months for GLD, to penetrate resistance … and then go into a vicious reversal.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Tech Talk, Moderna (MRNA)

Underside Test

Even though scenes like this one, this one and this one, are now common, the mainstream still seems to be ‘mystified’ as to the cause.

With all that happening as we speak, Moderna (MRNA) is finding itself potentially rising to test the underside of its trend line break.

Moderna (MRNA):

Weekly un-marked chart

Marked up with trendline break

Zoom in, of potential underside test area.

Summary:

Markets like to test … it’s what they do.

Sometimes, as with the gold hysteria, there’s a story to go along with the action. All intended to herd the easily led into the wrong side of the trade.

So, it could be with MRNA.

There’s all kinds of nastiness in the guise of ‘new strains’ out there; likely to raise their heads before Christmas and probably after as well.

These events may coincide with the previous post about biotech possibly heading for retrace and up-thrust.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Oil: Froth At The Top

XOP Down, XOM Up

Oil sector proxy XOP, posted outside-down (key reversal) while Exxon (XOM) closed higher.

If we’re in the middle of a reversal, this is normal.

Parts of the sector are already heading lower while typically, the larger caps are the last to complete the change.

This interview with Carter Worth, even though it’s short at only two-minutes thirty seconds, paints not-so-good picture.

He says in a typical scenario that’s repeated twice since the late April ’20 lows, oil has declined by 16% – 20%.

When asked how the equities would do, he hesitates, then says ‘It’s not worth the risk [to be long]’.

It’s a polite way to say they’re likely to get whacked.

Moderna (MRNA)

By now, everybody’s heard the news on Moderna.

Trouble for Moderna was spotted a while back and discussed in this post … along with a prediction that class-action may be forthcoming.

Our stopwatch is still ticking.

Positions

The account positions are short Oil & Gas XOP, using DUG as the vehicle (not advice, not a recommendation).

So far, its been a lot of banging around without much progress either way. However, at this point, a new low for DUG, below today’s low would signal trouble for the short side.

Stay Tuned

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279